Rapid Micro Biosystems, Inc.

NASDAQ:RPID

Medical - Devices

Healthcare
$1.11 +1.49%

+$0.03 today

Market cap
$50.31M
Beta
1.46
P/E (TTM)
-1.5
EPS (TTM)
-$1.10
52W Low $1.66High $4.94

Volume 0.17M

Average 0.18M

RPID Accounts Receivables

Cash effect of the change in amounts owed by customers; growing receivables consume cash.

Rapid Micro Biosystems, Inc.NASDAQ: RPID

Accounts Receivables · Q1 FY2026 · quarter ended Mar 2026

Accounts receivables turns negative

Q1 FY2026 accounts receivables was -$3.23M, compared with $3M a year earlier. Trailing-twelve-month accounts receivables was -$1.84M.

Context

  • Accounts receivables amounted to 13.1% of revenue in FY2025, up 6.0 pp from a year earlier.
  • Accounts receivables increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts receivables holds near -$3.23M or moves back toward the trailing-twelve-month quarterly average of -$461K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$3.23M-240.7% QoQ
Last fiscal yearDec 2025
$4.39M+320.8% YoY
LTMMar 2026
-$1.84M-561.0% YoY
Accounts Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-207.8%——
1 year+320.8%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Accounts Receivables history

USD · from the cash flow

Latest · FY2025
4.39M USD
Year-over-year change
+320.8%

Accounts Receivables vs competitors

How RPID compares with its peers on the latest reported figures

  • RPID's LTM Mar 2026 accounts receivables of $1.84M is the 4th largest of the 9 companies compared; the peer median is $254K.
  • Its year-over-year change of -561.0% is the 8th highest of 9, against a peer median of +46.3%.
  • Accounts receivables amounts to 5.4% of revenue for RPID, versus a peer median of 4.2%.
RPID Competitors Peer median
Accounts Receivables for RPID and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OWLTOwlet, Inc.LTM Mar 2026$3.32M -36.0%+8.9%3.1%
RCELAVITA Medical, Inc.LTM Mar 2026$3.09M +162.7%—4.3%
LNSRLENSAR, Inc.LTM Mar 2026$2.39M +188.7%—4.1%
RPIDRapid Micro Biosystems, Inc.LTM Mar 2026$1.84M -561.0%—5.4%
APYXApyx Medical CorporationLTM Mar 2026$1.31M -404.9%—2.3%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$1.12M +128.6%+72.7%—
LUCDLucid Diagnostics Inc.LTM Mar 2026$631K +5158.3%—12.3%
VANIVivani Medical, Inc.LTM Mar 2026$522K -769.2%——
SERASera Prognostics, Inc.LTM Mar 2026$14K -80.8%—24.6%
Peer median (excluding RPID) $254K+46.3%+40.8%4.2%

Competitors are the stored peer set for RPID. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(73.52M)(60.81M)(52.47M)(46.89M)(47.12M)
Depreciation & Amortization1.53M2.84M3.11M3.36M3.25M
Deferred Income Tax00000
Stock-Based Compensation1.84M4.02M4.75M3.87M4.03M
Change in Working Capital(8M)(5.33M)555K(4.77M)6.06M
Accounts Receivables(17K)(364K)(163K)(1.99M)4.39M
Inventory(6.77M)(5.84M)1.19M(335K)1.47M
Accounts Payables(524K)1.48M(3.46M)562K1.6M
Other Working Capital(691K)(602K)2.98M(3.01M)(1.39M)
Other Non-Cash Items23.19M728K(1.02M)271K2.71M
Operating Cash Flow(54.96M)(58.55M)(45.08M)(44.15M)(31.06M)
Capital Expenditures(3.22M)(6.74M)(1.85M)(1.37M)(850K)
Acquisitions (Net)00000
Purchases of Investments(25.09M)(179.23M)(62.49M)(35.04M)(27.08M)
Sales of Investments15M92.5M106.49M73.06M42.26M
Other Investing Activities20K0000
Investing Cash Flow(13.29M)(93.47M)42.15M36.66M14.33M
Debt Repayment(26.17M)(33K)(37K)(35K)19.09M
Common Stock Issued164.11M00238K1.1M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(940K)726K186K0(419K)
Financing Cash Flow216.75M693K149K203K19.77M
Effect of Forex Changes000(81K)0
Net Change in Cash148.49M(151.32M)(2.78M)(7.37M)3.04M
Free Cash Flow(58.18M)(65.29M)(46.93M)(45.52M)(31.91M)

Rapid Micro Biosystems, Inc.

NASDAQ:RPID

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.